Modern Retina Newsletter

To view this email as a web page, click here.

IL-6 inhibition shows promise as treatment for non-infectious uveitis

In a placebo-controlled phase 2 study of patients with severe non-infectious uveitis involving the posterior segment, subcutaneous sarilumab (Kevzara, Sanofi/Regeneron) demonstrated promising therapeutic activity.

Continue

Real-world study of the fluocinolone acetonide implant show its benefits for treating DME

A retrospective chart review study of patients who received the fluocinolone acetonide 0.19 mg implant (Iluvien, Alimera Sciences) for diabetic macular edema shows its efficacy and safety when patients are selected per the FDA-approved indication. Compared with the pre-implant period, visual acuity was maintained or improved and there were reductions in both treatment burden and the amplitude of retinal thickness fluctuation.

Find out

Diabetic eye disease: Best treatment options for your patients

Targeting angiopoietin-2 + VEGF-A to treat DME

Lessons learned from DRCR.net protocols

Achromatopsia: Understanding the rare inherited retinal disease

This is a post-only, outbound email. Please do not reply to this email as we will be unable to respond to your reply. Please use the links provided if you have questions or concerns regarding this email or your subscription.